Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 5/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28736819 | 0.81 | RAPGEF4 (0.43) | RAPGEF4HTR6MAPT | |
| SCHEMBL4316973 | 0.77 | RAPGEF4 (0.65) | CA1CA2RAPGEF4HTR6MAPT | |
| SCHEMBL28649703 | 0.77 | CA1 (0.44) | CA1CA2RAPGEF4HTR6THRB | |
| SCHEMBL15762149 | 0.77 | CA1 (0.47) | CA1CA2RAPGEF4HTR6LMNA | |
| SCHEMBL14125821 | 0.77 | CA1 (0.47) | CA1CA2RAPGEF4HTR6LMNA | |
| SCHEMBL30625972 | 0.76 | CA1 (0.43) | CA1CA2RAPGEF4HTR6THRB | |
| SCHEMBL29493317 | 0.73 | NPC1 (0.39) | CA1CA2LMNAMAPT | |
| SCHEMBL28904396 | 0.72 | CA1 (0.49) | CA1CA2RAPGEF4MAPTRECQL | |
| SCHEMBL28538858 | 0.72 | CA1 (0.49) | CA1CA2RAPGEF4MAPTRECQL | |
| SCHEMBL18951969 | 0.72 | CA1 (0.49) | CA1CA2RAPGEF4MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3959293-B1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRVANA SCIENCES INC (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20220249707-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRVANA SCIENCES INC. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3959293-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRvana Sciences Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2020236818-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRVANA SCIENCES INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-9417245-B2 | Porphyrinic compounds for use in flow cytometry | NORTH CAROLINA STATE UNIVERSITY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9417245-B2 | Porphyrinic compounds for use in flow cytometry | NORTH CAROLINA STATE UNIVERSITY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9417245-B2 | Porphyrinic compounds for use in flow cytometry | NORTH CAROLINA STATE UNIVERSITY (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150153350-A1 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-20150153350-A1 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-20150153350-A1 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-8187824-B2 | Porphyrinic compounds for use in flow cytometry | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8187824-B2 | Porphyrinic compounds for use in flow cytometry | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090227553-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-10 | — | — | US | disclosed |
| US-20090227553-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-10 | — | — | US | disclosed |
| US-20090227553-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-10 | — | — | US | disclosed |
| US-20090075295-A1 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-19 | — | — | US | disclosed |
| US-20090075295-A1 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-19 | — | — | US | disclosed |
| US-20090075295-A1 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-19 | — | — | US | disclosed |
| WO-2007064841-A2 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY | NORTH CAROLINA STATE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064842-A2 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | NORTH CAROLINA STATE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249707-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | AQP4, CLSPN, CHLSN | CA1 165/4885CA2 835/4885RAPGEF4 3752/4885 |
| US-20090227553-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | CRY1, CRY2, HCCS | CA1 2283/4885CA2 231/4885RAPGEF4 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.